07 Jan 2001

Bonifen 300 - España

Updated: 07 Jan 2001

Bonifen 300 mg 30 capsulas

Autorizadas en España: Astenia. Insuficiencia cerebrovascular.

Bonifen 300 Description, Presentation and Dosage

Bonifen 300 Description

Bonifen 300 Drug Class Description

Psicoestimulantes

Bonifen 300 Drug Description

CAPSULAS

Bonifen 300 Presentation

Bonifen 300 Presentation

Oral. Adultos: 100 mg/8 h, pudiendo incrementarse la dosis diaria, en función de la respuesta clínica, hasta un máximo de 300 mg/8 h (900 mg/día). Niños (>2 años): hasta 480 mg/día. Niños (<2 años): hasta 160 mg/día. La administración de la última dosis diaria se aconseja hacerla antes de las cinco de la tarde, a fin de reducir la incidencia de insomnio.

Bonifen 300 Manufacturer

MERCK FARMA QUIMICA

Related Learning Zones

CLL Knowledge Centre and CME

CLL Knowledge Centre and CME

The Chronic Lymphocytic Leukaemia (CLL) Knowledge Centre contains useful information arranged within four main sections: ‘Disease Awareness’, ‘Events’, ‘Resources’, and 'CME'. Healthcare professionals will find information on pathophysiology, signs and symptoms of CLL, diagnosis, prognosis, treatment and management options, an upcoming events calendar and an external links listing,

The CME activity ‘Treatment Optimisation in Chronic Lymphocytic Leukaemia’ has been EACCME-accredited and awarded 1 CME credit. Test your knowledge by answering quiz questions based on patient case study scenarios.

Obesity CME series

Obesity CME series

This European Obesity Initiative CME series contains three online modules, which are ideal for healthcare professionals looking to widen their understanding of obesity as a serious medical illness. Each module is EACCME-accredited and free to complete. Successful completion of the series will earn participants a combined total of 5 European CME credits (ECMECs).

Bonifen 300 Dosage

Bonifen 300 Precautions, Reactions and Contraindications

Bonifen 300 Special Precautions

Bonifen 300 Adverse Reactions

Bonifen 300 Adverse Reactions

Los efectos adversos de este medicamento son, en general, infrecuentes aunque moderadamente importantes. Las reacciones adversas más características son: -Raramente (<1%): náuseas, vómitos, gastralgia, insomnio, excitación y agitación. -Excepcionalmente (<<1%): alteraciones renales (proteinuria, síndrome nefrótico) y alteraciones hematológicas (leucopenia, trombocitopenia) en tratamientos prolongados con dosis elevadas (900 mg/día de piritinol).

Related Drugs - Medicina tropical

Back to top